From Bench to Bedside: Immunotherapy for Prostate Cancer

被引:16
作者
Tse, Brian Wan-Chi [1 ]
Jovanovic, Lidija [1 ]
Nelson, Colleen Coyne [1 ]
de Souza, Paul [2 ]
Power, Carl Andrew [3 ]
Russell, Pamela Joan [1 ]
机构
[1] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia
[2] Univ Western Sydney, Sydney Sch Med, Ingham Inst Appl Med Res, Sydney, NSW 2170, Australia
[3] Univ New S Wales, Lowy Canc Res Ctr, Biol Resources Imaging Lab, Sydney, NSW 2052, Australia
关键词
ALLOGENEIC CELLULAR IMMUNOTHERAPY; REGULATORY T-CELLS; PHASE-I TRIAL; SIPULEUCEL-T; DOSE-ESCALATION; GM-CSF; ADAPTIVE IMMUNITY; CTLA-4; BLOCKADE; DOUBLE-BLIND; OPEN-LABEL;
D O I
10.1155/2014/981434
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, immunotherapy has also emerged as an option for the treatment of this disease following the approval of sipuleucel-T by the FDA in 2010. Immunotherapy is a rational approach for prostate cancer based on a body of evidence suggesting these cancers are inherently immunogenic and, most importantly, that immunological interventions can induce protective antitumour responses. Various forms of immunotherapy are currently being explored clinically, with the most common being cancer vaccines (dendritic-cell, viral, and whole tumour cell-based) and immune checkpoint inhibition. This review will discuss recent clinical developments of immune-based therapies for prostate cancer that have reached the phase III clinical trial stage. A perspective of how immunotherapy could be best employed within current treatment regimes to achieve most clinical benefits is also provided.
引用
收藏
页数:11
相关论文
共 91 条
  • [1] [Anonymous], 2011, NEW ENGL J MED
  • [2] [Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107
  • [3] Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy
    Antonarakis, Emmanuel S.
    Drake, Charles G.
    [J]. CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) : 258 - 265
  • [4] Arellano M, 2008, BIOL-TARGETS THER, V2, P13
  • [5] A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
    Arlen, PM
    Gulley, JL
    Parker, C
    Skarupa, L
    Pazdur, M
    Panicali, D
    Beetham, P
    Tsang, KY
    Grosenbach, DW
    Feldman, J
    Steinberg, SM
    Jones, E
    Chen, C
    Marte, J
    Schlom, J
    Dahut, W
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1260 - 1269
  • [6] Pox viral vaccine approaches
    Arlen, PM
    Kaufman, HL
    DiPaola, RS
    [J]. SEMINARS IN ONCOLOGY, 2005, 32 (06) : 549 - 555
  • [7] Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
    Arlen, PM
    Gulley, JL
    Todd, N
    Lieberman, R
    Steinberg, SM
    Morin, S
    Bastian, A
    Marte, J
    Tsang, KY
    Beetham, P
    Grosenbach, DW
    Schlom, J
    Dahut, W
    [J]. JOURNAL OF UROLOGY, 2005, 174 (02) : 539 - 546
  • [8] New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
    Attard, Gerhardt
    Richards, Juliet
    de Bono, Johann S.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1649 - 1657
  • [9] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
    Attard, Gerhardt
    Reid, Alison H. M.
    A'Hern, Roger
    Parker, Christopher
    Oommen, Nikhil Babu
    Folkerd, Elizabeth
    Messiou, Christina
    Molife, L. Rhoda
    Maier, Gal
    Thompson, Emilda
    Olmos, David
    Sinha, Rajesh
    Lee, Gloria
    Dowsett, Mitch
    Kaye, Stan B.
    Dearnaley, David
    Kheoh, Thian
    Molina, Arturo
    de Bono, Johann S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3742 - 3748
  • [10] Bilusic M., 2011, J CLIN ONCOLOGY S7